Short answer
Amneal Pharmaceuticals, Inc. (AMRX) filed an 8-K current report with the SEC on April 22, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Amneal agreed to acquire 100% of Kashiv for $375 million cash plus 28,942,108 shares, creating substantial cash and equity dilution exposure.
Amneal Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Amneal agreed to acquire 100% of Kashiv for $375 million cash plus 28,942,108 shares, creating substantial cash and equity dilution exposure
- Sellers may receive up to $350 million in U.S. regulatory milestone payments for six product candidates
- Additional royalties equal to 25% of excess annual gross profits apply for 12 years after closing
- Closing expected in the second half of 2026, subject to regulatory approvals and shareholder votes
- Independent conflicts committee approved the transaction despite certain sellers’ Amneal Group affiliations; five-year noncompetes support retention of Kashiv’s value
Item 2.02 · Results of Operations and Financial Condition
- Preliminary first-quarter results for period ended March 31, 2026
- Press release issued April 22, 2026, with financial details in Exhibit 99.1
- Preliminary status means figures may change before finalized reporting
Item 7.01 · Regulation FD Disclosure
- Conference call moved to April 22, 2026 from May 1, signaling accelerated communication on acquisition and preliminary Q1 results
- Investor presentation includes updated growth outlook and post-closing financial condition expectations
- Preliminary Q1 2026 results and acquisition details available through Amneal’s Investor Relations website
- Management may use presentation in ongoing investor and analyst communications, increasing visibility into transaction implications
Item EX-99.1 · Exhibit EX-99.1
- Kashiv acquisition for $375M cash plus $375M equity, with up to $350M regulatory milestones and potential royalties
- Transaction targets $400M-$500M financial benefits and more than $300B biologics loss-of-exclusivity opportunity
- Closing expected second half 2026, subject to shareholder and regulatory approvals
- Preliminary Q1 revenue $723M, up 4%; adjusted EBITDA $202M, up 19%; adjusted diluted EPS $0.27, up 29%
- 2026 adjusted EBITDA guidance raised to $740M-$770M and operating cash flow to $350M-$400M
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Amneal Pharmaceuticals, Inc. 8-K filings
Get the next AMRX 8-K as it lands
Follow AMRX for push alerts, or ask the research agent what this filing means.